SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending amid discussion of deep sea mining's potential and recent UBS and Nature articles highlighting the value of deep sea mineral resources. Community members are actively debating price targets, potential for a short squeeze, and the company's long-term prospects in the critical minerals sector, especially in relation to shipbuilding and defense. Some investors are also weighing the impact of potential government stakes and regulatory decisions on TMC's future.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending as biotech sees a surge in interest, fueled by AI advancements and potential sector rotation, though some caution that the rally may be overextended. The community is debating whether current bullish sentiment is sustainable, considering factors like upcoming economic data and geopolitical events. Discussions also include individual stock analyses and potential impacts of rate cuts and tariff policies on the sector.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

ORCA is trending as traders discuss potential breakout levels and upcoming catalysts, while some community members are assessing ideal entry points and long-term recovery prospects. There's excitement building around its potential within the Solana ecosystem and predictions for substantial gains, with some eyeing a move past $3 as key to unlocking further upward momentum. Community members are also discussing recent developments in Orca's Dynamic Tick Arrays and Adaptive Fees, which could lead to tighter spreads, more liquidity, and strategic advantages during market volatility.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending amid discussions of a potential acquisition of a security startup and community anticipation for a stock split, even as some express concerns about recent price action. Despite a year-to-date decline, some investors view NOW's AI capabilities as undervalued compared to peers like Microsoft, while others debate whether the company can translate AI investments into top-line growth. Option activity and analyst ratings remain mixed, contributing to the ongoing community discussion.

ETF Opportunities Trust - T-REX 2X Long BMNR Daily Target ETF

T-REX 2X Long BMNR Daily Target ETF

$BMNU is trending due to its leveraged exposure to $BMNR, attracting traders aiming to amplify potential gains from a rebound in the crypto market, particularly Ethereum. Community members are actively discussing entry points, profit-taking strategies, and its potential for significant upward movement, with some expressing concerns about its tracking accuracy relative to $BMNR and potential reverse splits.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

ZS is trending due to its recent earnings report and subsequent analyst activity, with community members discussing whether the stock's reaction is an overdone sell-off or a justified correction. Despite positive earnings, some investors are concerned about guidance and valuation, while others see it as a buying opportunity. Broader sector trends and AI security are also influencing the conversation around ZS.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending amid buyout speculation and positive Q3 earnings, which showcased strong Lupkynis sales growth and promising progress with AUR200. Community discussions revolve around potential BO prices, patent extension timelines, and the impact of recent developments surrounding a former FDA official. Optimism is fueled by increased institutional ownership and analysts raising price targets, though the community remains wary due to the stock's volatile history.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) Public Ltd Co - Ordinary Shares - Class A

SMX is trending due to a recent Zacks Small Cap Research report and speculation of a short squeeze, sparking bullish sentiment. The community is actively discussing the potential for further gains, referencing its unique technology and recent partnerships, while some caution against potential dilution and past reverse splits. High short borrow fees and low float are contributing to the intense trading activity.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic ($SYM) is trending as traders discuss its bullish market structure and potential for a significant price surge, fueled by volume-backed rallies and comparisons to other high-growth stocks. Community members are analyzing revenue multiples, anticipating a short squeeze, and eyeing potential price targets, contributing to the increased attention on the stock. Bullish sentiment appears to be dominating discussions surrounding the AI-driven robotics and automation company.

Amentum Holdings, Inc. provides mission-critical, technology-driven services in government and commercial markets. It operates through two operating segments: Critical Mission Solutions and Cyber & Intelligence. The Critical Mission Solutions segment provides test, training, and operations services for missile defense systems, IT and engineering services to defense clients and the space sector, technological solutions, including installations, decommissioning, and environmental remediation to energy clients, and other highly technical consulting solutions. The Cyber & Intelligence segment provides advanced cyber training and data analytics for government professionals, advanced communication systems and aerial mapping technologies to national security clients, and other technical services for United States defense and intelligence clients. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

AMTM is trending due to a combination of factors, including recent analyst upgrades and mentions of a potential pro-nuclear energy stance. Bullish sentiment is fueled by the company's strong presence in the nuclear sector and significant government contracts, with the community discussing its potential for growth and comparing it to other high-performing stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ascendiant Capital Markets Cuts Plus Therapeutics (NASDAQ:PSTV) Price Target to $19.00

Ascendiant Capital Markets decreased their price target on shares of Plus Therapeutics from $21.00 to $19.00 and set a "buy" rating on the stock in a research note on Friday...

&nbsp;November 20, 2025<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.plustherapeutics.com/node/17491/pdf">PDF Version</a>HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=-LjgaMRZ499BxpnVFdK1_OIruUYH174LnCXs-fy9J1I_eFQqC3JpTBwOvH766dIT1nH5xLfntIINbP5tEdkB0SDLQG78HFGAOU5BkEJHktWlDyLHpCuy4sMdy9V6Ic4WNMutQlg4-mtVdYtWYaiL2IGkfMeZRCJwGfExniMB_2c8rF2BDTDExok63zegxo0Zzz8pCRIM_zGVoZ1pjMraVCsb47ACHDjHfm535tp8HDAGNMMlGzQxU4v50bSczESWKo6x314ti5HzsTYfN5TjFKj_R0Svs0TsL0Fpuw4o_V2QfDL515ej-QxrOcQDGzj83Xv55B3FzhnQtPM8CwzhHpEEtGvzFWKaNufvlmTXXGcjoyYpySS0ASePbFZjDn0SFCVDnbn2ujI2mvrDFn_YPj4uRtUZKd_u84vRPxhML9hM-8bd2N6am39WyHccsrghDSIS-9PtjI-w5QT1fbwrMTOplD0Zgp5-7lDPMm_u6rKd-HDKnSTsf1VW9kP-ssxp">Plus Therapeutics, Inc.</a>&nbsp;(Nasdaq:&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=Qc6X8S3RzScKVxvNu5_ceEM5GEv1Pptj0kvVK2trVYTrKl52rKHptUJcMeFv_r8m6XJ1xYecZnTL9qsMJK-c4D7wONMnr4cOMHuhbyC-B_5ohVVGYSzEJF3Bkl7p1l7wVA64zTIak8hwab7N7Mq556tOQzJlP6kOnE85RNx-iO3w5Wba49-0HAevN_Q0AzurlwzNjWv5cenpZgxc6bFvdrGmTjJRaW_JSEuTLAnXmNlti0LfISAeX284Eg18Lpu6kaosboSHHlT-jVrzzC9bF_XHIR2lKjlwRHyA34hiRVgqvNNrk9BKENa4lSbOz0hxdMgude4ZKO_7LMkYeJ78D5qOqeh8jDUAgckGvzK6XSj4sPM3rAs4MMrV6u79J2HmkaRunbqmC4i9TaFzG2JElk80i-xPqB7Ud8a_0MZs9BXT5C7FRTNYAtbyUh38Wl1-">PSTV</a>) (“Plus” or the “Company”), announced today that it has signed a national agreement with Humana, Inc. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=Ckx5KRl7GkjOTsknevCsv0V8yLayXt9wPOfKjhKbZbbUPUtJYQQ1s_3WMPrcWwJKkvtnm3wVcl2NqQk3TgY1p2feIGsp1Q-lDBhIyjds9Qo=">HUM</a>), effective&nbsp;October 29, 2025, covering approximately 16 million people throughout&nbsp;the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory developed test (LDT). This brings CNSide CSF TCE LDT total policy coverage to 67 million people.The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases.This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.About CNSide Diagnostics, LLC&nbsp; CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=_L7AJZWxKXphoarOFZy8Z85jinISrbvcaCeYclceVpAt9mO3Wi78ljN4HTR9BVI1smJG5x77F_beqPHrp5vSTUx_fkwpPQaECwHXeOdYGN4=">https://www.cnside-dx.com/</a>.About Plus Therapeutics Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=_L7AJZWxKXphoarOFZy8Z35nW-kNODbXQZtlDECdtGDGWCcawXezTzcic5Wa0-GT7YTxFESUvgVo1SXipvsyvJqzICHTRIfUoONu9xOH9uwwt2yHEFxsHOOelgYY9iSs">https://www.plustherapeutics.com</a>.About HumanaHumana Inc. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=sVqa190sv-OGip6yFjYGO0t_cm6VKwY3aysRDxYxSjt0DTCbL2OqMK2Oz0V0BVN0kxVxe1yu5iCIPHAl4xJijJT_ANoSx8Di9opJClAXJ3U=">HUM</a>) is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.Forward-Looking Statements This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.Investor Contact CORE IR <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investor@plustherapeutics.com">investor@plustherapeutics.com</a>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

CNSide Diagnostics, a Plus Therapeutics subsidiary, secured a national agreement with Humana to provide its CNSide CSF Tumor Cell Enumeration test, expanding coverage to 67 million people.

Others

Plus Therapeutics (NASDAQ:PSTV) Receives "Buy" Rating from D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and set a $5.00 target price on shares of Plus Therapeutics in a research note on Thursday...

Plus Therapeutics (NASDAQ:PSTV) Downgraded to "Hold" Rating by Zacks Research

Zacks Research lowered shares of Plus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday...

Plus Therapeutics (NASDAQ:PSTV) CFO Andrew John Hugh Macintyr Sims Buys 20,000 Shares

Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) CFO Andrew John Hugh Macintyr Sims acquired 20,000 shares of the firm's stock in a transaction on Tuesday, November 4th. The shares were bought...

Plus Therapeutics (NASDAQ:PSTV) CFO Buys $10,200.00 in Stock

Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) CFO Andrew John Hugh Macintyr Sims purchased 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 4th. The...

Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates

Plus (PSTV) delivered earnings and revenue surprises of -100.00% and -36.79%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Beats Q3 Earnings Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of +3.92% and -2.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15, 2025 Equity Insider News...

Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics

Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.03	-$0.77	-2269.23%	MISSED
Q3 '25	-$0.02	-$0.04	-100.00%	MISSED
Q2 '25	-$0.09	$0.02	121.95%	BEAT
Q1 '25	-$0.25	-$1.19	-379.69%	MISSED
Q4 '24	-$0.50	-$0.38	23.49%	BEAT

PSTV
Plus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest PSTV News

PSTVPlus Therapeutics Inc